Evidence map›Paper›PMID 35005477›Full record

ArticleIJU case reports2022

Double renal cell carcinoma with histological type of clear cell carcinoma and papillary carcinoma in the same kidney concurrently treated with robot-assisted partial nephrectomy.

Teruki Shimizu, Fumiya Hongo, Hikaru Takahashi, Atsuko Fujihara, Osamu Ukimura

Open access · goldAbstract readCase Reports
In one paragraph

Article in IJU case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Teruki ShimizuDepartment of Urology Kyoto Prefectural University of Medicine Kyoto Japan.ORCID https://orcid.org/0000-0002-7470-8840
Fumiya HongoDepartment of Urology Kyoto Prefectural University of Medicine Kyoto Japan.ORCID https://orcid.org/0000-0002-1991-4166
Hikaru TakahashiDepartment of Urology Kyoto Prefectural University of Medicine Kyoto Japan.
Atsuko FujiharaDepartment of Urology Kyoto Prefectural University of Medicine Kyoto Japan.
Osamu UkimuraDepartment of Urology Kyoto Prefectural University of Medicine Kyoto Japan.
Kyoto Prefectural University of Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe presence of two different histologic types of renal cell carcinoma in the same kidney is rare in clinical practice. This report describes a patient with ipsilateral renal cell carcinomas, consisting of a clear cell renal cell carcinoma and a papillary type 1 renal cell carcinoma, who was successfully treated by robot-assisted partial nephrectomy. CASE PRESENTATION: A 70-year man was referred to our hospital for the treatment of two right mid-pole renal tumors, measuring 51 mm and 31 mm in diameter. The two tumors, which differed in contrast enhancement on computed tomography, were removed simultaneously by robot-assisted partial nephrectomy. Histopathological and immunohistochemical findings confirmed that one tumor was a clear cell renal cell carcinoma, pT1a, and the other was a papillary type1 renal cell carcinoma, pT1b.

conclusionThis report describes a rare patient presenting with two ipsilateral renal cell carcinomas differing in histology. Robot-assisted partial nephrectomy was the safe and effective nephron-sparing surgery, even in patients with complex double renal tumors.

Indexed as

clear cell renal carcinomaipsilateralpapillary type1 renal cell carcinomarobot‐assisted partial nephrectomy

Identifiers

PMID35005477
PMCPMC8720717
OpenAlexW4200348047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.